Altimmune: Why I'm Downgrading To Hold Despite MASH Promise (NASDAQ:ALT)
Summary
Altimmune (ALT) shifts to MASH with pemvidutide; Phase 2b data and FDA Breakthrough show promise, but rivals loom. Click here to read my latest analysis.
Description
Altimmune (ALT) shifts to MASH with pemvidutide; Phase 2b data and FDA Breakthrough show promise, but rivals loom. Click here to read my latest analysis.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source